A multicentre, double-blind, randomized, placebo-controlled study to evaluate the efficacy and the safety of ALF-5755 in patients with nonacetaminophen severe acute hepatitis and early stage acute liver failure

Registry ID

EUCTR2010-020657-14

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Alfact Innovation

Start date

2011-07-04

Completion date

2013-04-24

Last update

2026-08-16

Conditions

• Acute liver failure

Summary

To evaluate the efficacy of ALF-5755 versus placebo, measured by rate of change of prothrombin ratio (PR) during the 72 hours following treatment initiation, in patients with nonacetaminophen SAH and early stage ALF.

Locations

• , , Germany

View on source registry